ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: ICARIA-MM SUBGROUP ANALYSIS

• M.E.Z. Capra,
• M. Beksac,
• P.G. Richardson,
• A. Unal,
• P. Corradini,
• S. Delimpasi,
• Z. Gulbas,
• G. Mikala,
• A. Neylon,
• A. Symeonidis,
• S. Bringhen,
• P. Moreau,
• H.V. Velde,
• F. Campana,
• S.L. Guennec,
• I. Spicka

Affiliations

M.E.Z. Capra

Hospital Mãe de Deus, Porto Alegre, RS, Brazil

M. Beksac

Department of Hematology, Ankara University, Ankara, Turkey

P.G. Richardson

Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States

A. Unal

Department of Hematology, Erciyes University Medical School, Kayseri, Turkey

P. Corradini

Division of Hematology, Istituto Nazionale dei Tumori, University of Milano, Milan, Italy

S. Delimpasi

Department of Haematology, General Hospital of Athens, Athens, Greece

Z. Gulbas

Anadolu Medical Center, Kocaeli, Turkey

G. Mikala

Department of Hematology and Stem Cell Transplantation, South Pest Central Hospital, Budapest, Hungary

A. Neylon

Department of Haematology, Dunedin Hospital, Dunedin, New Zealand

A. Symeonidis

Hematology Division, Department of Internal Medicine, University of Patras Medical School, Patras, Greece

S. Bringhen

Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy

P. Moreau

Hematology Department, Nantes University Hospital, Nantes, France

H.V. Velde

Sanofi R&D, Cambridge, United States

F. Campana

Sanofi R&D, Cambridge, United States

S.L. Guennec

Sanofi R&D, Vitry-Sur-Seine, France

I. Spicka

1st Department of Medicine – Department of Hematology First Faculty of Medicine Charles University and General Hospital in Prague, Prague, Czech Republic